Zimmer Biomet Holdings (ZBH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $2.07
- Estimate
- $2.01
- Surprise
- +3.0%
- Revenue (period 2026-06-30)
- $2.18B
- Score today
- 6.1/10
Revenue source: xbrl.
How the report landed
Zimmer Biomet Holdings (ZBH) beat the $2.01 estimate with adjusted EPS of $2.07 — a modest 3.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZBH Hold at 6.1/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +3.0% surprise compares with a +4.5% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: single-source materials and components
- Thin upside margin: 6.5%
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $90.86
- Price target
- $96.81
- Stop
- $87.17
- Upside to target
- +6.5%
- Reward-to-risk
- 1.0:1
The stock trades at 22.1× trailing but 10.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
ZBH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $17.33B
- P/E (fwd)
- 10.0
- P/E (ttm)
- 22.1
- 52-week range
- $79.12–$106.88
- Off 52-week high
- 15.0%
- RSI (14)
- 32
- Volume vs avg
- 0.14×
- Score today
- 6.1/10